Anti-cancer gene radioiodine therapy using the NIS: A very promising approach

作者：Bellaoui W^*; Ghfir I; Guerrouj H; Aouad N Ben Rais

来源：Medecine Nucleaire-Imagerie Fonctionnelle et Metabolique, 2011, 35(10): 537-544.

DOI：10.1016/j.mednuc.2011.06.012

• Sodium iodide
• Symporter
• Gene therapy
• Radioiodine therapy

The symporter Na/iodine (NIS) is a recently discovered membrane protein, recognized to be at the origin of accumulation of iodine in the thyroid, salivary glands, stomach and mammary glands during lactation. If its intrinsic property served as the basis for nuclear imaging and radiotherapy metabolic of differentiated thyroid cancers and their metastases, the cloning of its gene provides a powerful strategy for cytoreductive gene therapy, based on the targeted transfer of this last one in all types of cancer cells. Its expression gives the ability to these cells to accumulate iodine. The aim is to benefit from the advantages of radioiodine therapy (efficiency, reduced side effects) and to optimize the management. of thyroid cancer. This approach offers an attractive therapeutic alternative for non-thyroidal cancers, especially in the context of a multimodal approach. Techniques and equipments necessary for the first clinical trials are already existing in the departments of nuclear medicine. The perspectives of clinical application, however, require a better knowledge of the regulation of expression and functionality of NIS. After a review of the biology of NIS, our work aims to recount the results of different tests that have demonstrated the benefits of this approach, its limitations and prospects for its improvement.

• 出版日期2011-10